The United States Food and Drug Administration recently approved Tonmya TM (cyclobenzaprine hydrochloride sublingual tablets) ...

TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Unique sublingual formulation designed for bedtime dosing bypasses first-pass ...

Credit: Tonix Pharmaceuticals. Tonmya is a once-daily sublingual tablet of cyclobenzaprine HCI taken at bedtime for the treatment of fibromyalgia. Clinical trials have demonstrated that Tonmya reduces ...

CHATHAM, N.J., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (TNXP), a fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) ...

Buprenorphine sublingual tablet is prescribed to treat opioid use disorder in two phases: an induction phase to manage initial withdrawal symptoms and a maintenance phase for long-term treatment. You ...

Please provide your email address to receive an email when new articles are posted on . Tonmya significantly reduced daily pain vs. placebo in a phase 3 trial in fibromyalgia. Fast track designation ...

Treatment was well tolerated with minimal effects on weight or blood pressure and discontinuation rate of 19% vs. placebo of 20.8% Data support the potential of Tonmya as a well-tolerated, centrally ...

New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and ...

New sublingual delivery system designed to enhance bioavailability and avoid gastric side effects many patients experience with clopidogrel.

Microsize brings over thirty years of expertise in specialized particle size engineering for the pharmaceutical industry, ...